New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has noted the post-marketing surveillance report of the Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules”.
This came after the vaccine major Biological E presented the post-marketing surveillance report of the Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post-marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules”.
Hepatitis B Vaccine (Recombinant) is composed of highly purified hepatitis B surface antigen (HBsAg) adsorbed to an aluminum adjuvant. The antigen is produced from the fermentation of a recombinant strain of yeast, Saccharomyces cerevisiae.
At the recent SEC meeting for Vaccine 30th April 2024, the expert panel reviewed the post-marketing surveillance report of Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules" presented by the drug major Biological E.
After detailed deliberation, the committee noted the results of the PMS study as presented by the firm.
from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/fJwoAOm
0 Comments